Self-injections Market by Type (Auto-Injectors, Needle-free Injectors, Pen Injectors), Usage (Disposable, Reusable), Distribution Channel, Therapeutic Areas Application - Global Forecast 2024-2030
Description
Self-injections Market by Type (Auto-Injectors, Needle-free Injectors, Pen Injectors), Usage (Disposable, Reusable), Distribution Channel, Therapeutic Areas Application - Global Forecast 2024-2030
The Self-injections Market size was estimated at USD 54.00 billion in 2023 and expected to reach USD 60.64 billion in 2024, at a CAGR 12.72% to reach USD 124.87 billion by 2030.
Self-injections refer to the products used to administer medication to themselves intramuscularly, subcutaneously, or intravenously without the immediate assistance of healthcare professionals. Self-injections are used for treatments that require regular and long-term care, such as insulin for diabetes, hormones for hormone replacement therapy and fertility treatments, and biologics for chronic conditions. Self-injection devices are widely used to increase autonomy and can improve treatment adherence by eliminating the need for healthcare provider administration. An elevating prevalence of chronic diseases, the need for home-based healthcare, advancements in drug delivery technology, and a growing patient preference for self-administration have improved the usage of self-injections in recent years. However, the requirement for significant investment in research and development, patient safety and comfort concerns, and the need for cold chain storage and logistics for biologics limit the product penetration of self-injections. Recognition of digitization and patient-centricity leads to opportunities for integrating smart technology into self-injection devices. Innovations focusing on connectivity can provide data collection, patient monitoring, and adherence tracking, guiding personalized treatment modalities for self-injections. Moreover, the supportive government approvals for self-injections are further expanding the scope of the market.
Regional Insights
The self-injections market in the Americas is driven by a strong emphasis on patient-centric care, advanced healthcare infrastructure, and an increase in biologic drug approvals that require patient-friendly administration. Consumers are becoming increasingly aware of self-care options, including self-injection devices, which align with convenience. Government initiatives to reduce hospital stays and promote self-administration of medication also contribute to the penetration of self-injections in the Americas. In the European Union, market growth for self-injection devices is supported by an aging population, the prevalence of chronic diseases, and a strong inclination toward self-management of these conditions. The EU's rigorous regulatory framework ensures high safety standards for self-injection devices. Furthermore, several EU countries have been active in running patient education programs to encourage the adoption of self-injection practices. In the Middle East and Africa, substantial investments in healthcare infrastructure and an increasing incidence of lifestyle-related diseases show promising growth for the self-injections market. In the Asia-Pacific region, rapid economic growth and increased healthcare expenditure are major drivers for the self-injections market. The government's emphasis on pharmaceutical innovation and the surging prevalence of chronic diseases are boosting demand. Furthermore, a technologically advanced healthcare system and an aging population enable the market for self-injection devices in the Asia Pacific.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Self-injections Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rapid prevalence of chronic diseases and rheumatoid arthritis
- Wide availability of self-injections for fertility treatments
- Market Restraints
- Potential risk of product recall
- Market Opportunities
- Ongoing government approvals for self-injections worldwide
- Technological advancements in self-injection devices
- Market Challenges
- Limited awareness and administration challenges associated with self-injections
- Market Segmentation Analysis
- Type: Rising preference for pen injectors to manage chronic diseases
- Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
- Distribution Channel: Emerging penetration of self-injections on online platforms
- Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Self-injections Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Self-injections Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
Atlanta-based Micron Biomedical secured a substantial USD 23.6 million investment from the Bill & Melinda Gates Foundation, earmarked for scaling up the production of its revolutionary needle-free vaccines. Employing advanced microarray technology, these vaccines offer a virtually pain-free administration through a simple press of a button. This innovation simplifies the vaccination process and significantly reduces reliance on the cold chain, allowing community health workers to promptly vaccinate children, thereby expanding access to preventive care in low and middle-income regions.
Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
Enable Injections achieved a significant milestone with the first approval from the U.S. Food and Drug Administration (FDA). The FDA's authorization marks a pivotal step forward for Enable Injections, reinforcing their commitment to advancing self-injection technology, and providing patients with innovative solutions for drug delivery. This approval, detailed in a press release, underscores the company's dedication to quality and safety in developing user-centric devices that simplify the administration of high-volume, subcutaneous injections for various therapies.
Altaviz introduces New Auto-Injector Platform For Drug Delivery
Altaviz's introduced auto-injector platform aids in revolutionizing self-administered medical treatments. This state-of-the-art system is meticulously designed to address various challenges associated with traditional injectable drug delivery, such as improving patient adherence, enhancing ease of use, and minimizing discomfort. By integrating sophisticated technologies, Altaviz's auto-injector offers a highly intuitive solution that empowers patients to manage their treatments effectively and with confidence.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Self-injections Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Self-injections Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma, Inc. by Halozyme, Inc., AstraZeneca plc, Baxter International, Inc., Becton, Dickinson and Company, Credence MedSystems, Inc., DALI Medical Devices Ltd., Eli Lilly and Company, Enable Injections, Inc., Gerresheimer AG, GlaxoSmithKline plc, Insulet Corporation, Johnson & Johnson Services, Inc., Medmix AG by Sulzer Ltd., Merck KGaA, Molex LLC by Koch Industries, Inc., Mylan N.V. by Viatris Inc., Novo Nordisk A/S, Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet, Inc., Recipharm AB, Sanofi S.A., SCHOTT AG, SHL Medical AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services, Inc., and Ypsomed Group.
Market Segmentation & Coverage
This research report categorizes the Self-injections Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Auto-Injectors
- Needle-free Injectors
- Pen Injectors
- Wearable Injectors
- Usage
- Disposable
- Reusable
- Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Private Clinics
- Therapeutic Areas Application
- Autoimmune Diseases
- AIDS
- Allergies
- Cancer
- Irritable Bowel Disorders
- Multiple Sclerosis
- Psoriasis
- Emergency Drugs
- Anaphylactic Socks
- Migraine
- Hormone Replacement Therapies
- Beta-Interferon
- Erythropoietin
- Follicle Stimulating Hormone
- Heparin
- Insulin
- Parathyroid Hormone
- Parkinson’s
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Autoimmune Diseases
- Market Drivers
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rapid prevalence of chronic diseases and rheumatoid arthritis
- 5.1.1.2. Wide availability of self-injections for fertility treatments
- 5.1.2. Restraints
- 5.1.2.1. Potential risk of product recall
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing government approvals for self-injections worldwide
- 5.1.3.2. Technological advancements in self-injection devices
- 5.1.4. Challenges
- 5.1.4.1. Limited awareness and administration challenges associated with self-injections
- 5.2. Market Segmentation Analysis
- 5.2.1. Type: Rising preference for pen injectors to manage chronic diseases
- 5.2.2. Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
- 5.2.3. Distribution Channel: Emerging penetration of self-injections on online platforms
- 5.2.4. Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
- 5.3. Market Trend Analysis
- 5.3.1. Rising incidents of diabetes and chronic diseases creating need for self-injections in the Americas
- 5.3.2. Growing investment in healthcare infrastructure and innovation in self-injections devices in APAC region
- 5.3.3. Supportive government approvals for self-injections in the EMEA region
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Self-injections Market, by Type
- 6.1. Introduction
- 6.2. Auto-Injectors
- 6.3. Needle-free Injectors
- 6.4. Pen Injectors
- 6.5. Wearable Injectors
- 7. Self-injections Market, by Usage
- 7.1. Introduction
- 7.2. Disposable
- 7.3. Reusable
- 8. Self-injections Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Hospital Pharmacies
- 8.3. Online Pharmacies
- 8.4. Private Clinics
- 9. Self-injections Market, by Therapeutic Areas Application
- 9.1. Introduction
- 9.2. Autoimmune Diseases
- 9.3. Emergency Drugs
- 9.4. Hormone Replacement Therapies
- 10. Americas Self-injections Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Self-injections Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Self-injections Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
- 13.3.2. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
- 13.3.3. Altaviz introduces New Auto-Injector Platform For Drug Delivery
- 13.3.4. FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH
- 13.3.5. Civica Partners With Ypsomed For Insulin Injection Pen
- 13.3.6. Eitan Medical Completes Transition of Wearable Injectors Business
- 13.3.7. Coherus Announces U.S. Launch of UDENYCA Autoinjector
- 13.3.8. Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
- 13.3.9. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
- 13.3.10. US FDA Approves Tezspire For Self-Administration Using Pre-Filled Pen
- 13.3.11. Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
